RxDoctor Payments Data

Kristy Hernandez

Family Medicine · Reading, PANPI 1659053312

Payments from drug & device makers

$5,563in general payments, 2019–2025

Across 270 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$862
  • AstraZeneca$783
  • Pfizer$558
  • Lilly USA, LLC$478
  • Novartis$231
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$5,46498%
  • Education$982%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,563 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$88,094
Medicare patients
371
Services billed
1,035

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide35$31,998
EliquisApixaban35$31,330
MounjaroTirzepatide30$29,478
JanuviaSitagliptin Phosphate14$9,652
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$9,094
Fluticasone Propionate84$1,108
Metoprolol Succinate35$782
Albuterol Sulfate HfaAlbuterol Sulfate21$651
Atorvastatin Calcium64$647
Omeprazole62$634
Rosuvastatin Calcium34$606
Bupropion XlBupropion Hcl17$574
Lisinopril87$554
Levothyroxine Sodium79$543
Valsartan17$513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,245$31,99835 claims
PfizerEliquis$558$31,33035 claims
Lilly USA, LLCMounjaro$478$29,47830 claims
MerckJanuvia$37$9,65214 claims
GSKTrelegy Ellipta$64$9,09411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Reading

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →